An official website of the United States government
Home
Name
Denosumab
Alternate Names
Prolia
Xgeva
Abbreviations
None
Category
Ancillary Agent
Biologic therapy (BRM, immunotherapy)
Subcategory
PLEASE SEE IMPORTANT CODING INFORMATION IN REMARKS FIELD
RANKL inhibitor
NSC Number
None
Primary Site
Histology
Remarks
IMPORTANT CODING NOTE (JULY 12, 2013): This drug was approved by the FDA on June 13, 2013 to treat unresectable giant cell tumors of the bone in both adults and skeletally mature adolescents. If this drug is being prescribed to treat this type of tumor, code as BRM/Immunotherapy.
For all other conditions below, do not code, the drug is considered ancillary.
November 18, 2010: Received FDA approval for the prevention of skeletal-related events in patients with bone metastases from solid tumors or in multiple myeloma.
Indicated for prevention of bone-related events in multiple myeloma
Indicated for treatment of hypercalcemia of malignancy
Denosumab is used to treat osteoporosis
For all other conditions below, do not code, the drug is considered ancillary.
November 18, 2010: Received FDA approval for the prevention of skeletal-related events in patients with bone metastases from solid tumors or in multiple myeloma.
Indicated for prevention of bone-related events in multiple myeloma
Indicated for treatment of hypercalcemia of malignancy
Denosumab is used to treat osteoporosis
Coding
Please see remarks for additional information
